Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
Combination of azacitidine (AZA) for 7 days every 28 days with a continuous daily exposure to Venetoclax (VEN), an oral bcl-2 inhibitor, is now approved for the treatment of acute myeloid leukemia (AML) in patients ineligible for intensive chemotherapy due to age (>75 years) or comorbidities. VEN+AZA showed significant overall response rate and survival benefit but combination carries a risk of considerable toxicity (such as profound/prolonged cytopenia and infections) before but also after remission. These toxicities make it difficult to apply the recommended treatment regimen, in particular the continuous daily intake of VEN. Recent reports suggest that reducing VEN duration per cycle seems safe and feasible. We propose to investigate a reduced-intensity VEN regimen (7-day dosing/28) versus the standard continuous VEN therapy (28-day dosing/28), combined with AZA, with the primary goal of maintaining efficacy while reducing associated toxicity.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Subject must have confirmation of AML by WHO 2022 criteria and be ineligible for treatment with a standard cytarabine and anthracycline induction regimen due to age or co-morbidities.
Subject must be ≥ 60 years of age.
Subject must have a projected life expectancy of at least 12 weeks.
Subject must be considered ineligible for induction therapy defined by the following:
75 years of age OR
60 to 74 years of age with at least one of the following co-morbidities:
Subject must have an Eastern Cooperative Oncology Group (ECOG) Performance status (Appendix 4):
Subject must have adequate renal function as demonstrated by a creatinine clearance ≥ 30 mL/min; calculated by the Cockcroft Gault formula.
Subject must have adequate liver function as demonstrated by:
(* Unless considered to be due to leukemic organ involvement. Subjects who are < 75 years of age may have a bilirubin of ≤ 3.0 × ULN)
Female subjects must be either postmenopausal (amenorrhea for at least 12 months with no alternative medical reasons) or surgically sterile (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).
Non-sterile male subjects must use contraceptive methods with partner(s) prior to beginning study drug administration and continuing up to 90 days after the last dose of study drug. Male subjects must agree to refrain from sperm donation from initial study drug administration until 90 days after the last dose of study drug.
Subject must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study specific procedures.
Patients must be affiliated to a social security system or beneficiary of the same
Patients shall be eligible to undergo Azacitidine and Venetoclax treatment and BM aspiration. Patients who either do not consent to a BM aspiration will not be eligible.
Exclusion criteria
Subject has received treatment with the following:
Subject has history of myeloproliferative neoplasm [MPN], including myelofibrosis, essential thrombocythemia, polycythemia vera, chronic myeloid leukemia (CML) with or without BCR-ABL1 translocation and AML with BCR-ABL1 translocation.
Subject has favorable risk cytogenetics such as t(8;21), inv(16), t(16;16) or t(15;17) as per the NCCN Guidelines Version 2, 2016 for Acute Myeloid Leukemia.
Subject has acute promyelocytic leukemia
Subject has known active CNS involvement with AML.
Known human immunodeficiency virus HIV
Known hepatitis B or C infection with the exception of those with an undetectable viral load within 3 months.
Subject has a cardiovascular disability status of New York Heart Association Class ≥ 2. Class 2 is defined as cardiac disease in which patients are comfortable at rest but ordinary physical activity results in fatigue, palpitations, dyspnea, or anginal pain.
Subject has chronic respiratory disease that requires continuous oxygen, or significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, or any other medical condition that in the opinion of the investigator would adversely affect his/her participating in this study.
Subject has a malabsorption syndrome or other condition that precludes enteral route of administration.
Subject exhibits evidence of other clinically significant uncontrolled systemic infection requiring therapy (viral, bacterial or fungal).
Subject has a history of other malignancies prior to study entry, with the exception of:
Subject has a white blood cell count > 25 × 109/L. (Hydroxyurea is permitted to meet this criterion.)
Subject has hypersensitivity to the active substances of any of the excipients
Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent
NB: patients with IDH1-mutant AML will not be formally excluded from the study. However, investigators are strongly encouraged to prefer treatment combining Azacitidine and Ivosidenib (AGILE phase III trial).
Primary purpose
Allocation
Interventional model
Masking
262 participants in 2 patient groups
Loading...
Central trial contact
Jean-Luc JOANNIC, PhD; Christophe WILLEKENS, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal